Label: MINZOYA- levonorgestrel and ethinyl estradiol and ferrous bisglycinate kit

  • NDC Code(s): 70748-322-14
  • Packager: Lupin Pharmaceuticals, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated January 9, 2025

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use MINZOYA safely and effectively. See full prescribing information for MINZOYA. MINZOYA (levonorgestrel and ethinyl estradiol tablets ...
  • Table of Contents
    Table of Contents
  • BOXED WARNING (What is this?)

    WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

    Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [see Contraindications (4)].

    Close
  • 1 INDICATIONS AND USAGE
    Minzoya™ is indicated for use by females of reproductive potential to prevent pregnancy.
  • 2 DOSAGE AND ADMINISTRATION
    2.1 How to Start Minzoya - Minzoya is dispensed in a blister card [see How Supplied/Storage and Handling (16)]. Minzoya may be started using either a Day 1 start or a Sunday start (see Table 1) ...
  • 3 DOSAGE FORMS AND STRENGTHS
    Minzoya (levonorgestrel and ethinyl estradiol tablets USP and ferrous bisglycinate tablets) is available in a 28-tablets compact blister card with: 21 White to off-white round biconvex tablets ...
  • 4 CONTRAINDICATIONS
    Minzoya is contraindicated in females who are known to have or develop the following conditions: • A high risk of arterial or venous thrombotic disease. Examples include women who are known ...
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Thrombotic Disorders and Other Vascular Problems -   Stop levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets if an arterial thrombotic event or venous ...
  • 6 ADVERSE REACTIONS
    The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ...
  • 7 DRUG INTERACTIONS
    Consult the labeling of concurrently used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. 7.1 Effects of Other ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - Risk Summary - Levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets are contraindicated in pregnancy because there is no reason to use combined hormonal ...
  • 10 OVERDOSAGE
    There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.
  • 11 DESCRIPTION
    Minzoya (levonorgestrel and ethinyl estradiol tablets USP and ferrous bisglycinate tablets) provides an oral contraceptive regimen consisting of 21 white to off-white active tablets and 7 blue ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - [see Warnings and Precautions (5.12) and Use in Specific Populations (8.1)]
  • 14 CLINICAL STUDIES
    In a clinical trial with levonorgestrel 0.1 mg and ethinyl estradiol 0.02 mg tablets, 1,477 women aged 17 to 49 years, had 7,720 cycles of use. Eighty-seven percent (87%) of the women were ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    16.1 How Supplied - Minzoya is available in a blister pack containing 28 tablets arranged in 3 rows of 7 active tablets and 1 row of inactive tablets, as follows:   21 active tablets: White to ...
  • 17 PATIENT COUNSELING INFORMATION
    See FDA-approved patient labeling (Patient Information and Instructions for Use). Counsel patients on the following information: Cigarette smoking increases the risk of serious cardiovascular ...
  • SPL UNCLASSIFIED SECTION
    Distributed by: Lupin Pharmaceuticals, Inc. Naples FL, 34108 - United States. Manufactured by: Lupin Limited - Pithampur (M. P.) - 454 775 - India. Revised: September 2024
  • PATIENT PACKAGE INSERT
    PATIENT INFORMATION - Minzoya™ (min-ZOYA) (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets) for oral administration - What is the most important information I ...
  • SPL UNCLASSIFIED SECTION
    Instructions For Use - MinzoyaTM – (min-ZOYA) (levonorgestrel and ethinyl estradiol tablets and ferrous bisglycinate tablets) for oral administration - Important Information about taking ...
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
    BLISTER LABEL - MINZOYATM (levonorgestrel and ethinyl estradiol tablets, and ferrous bisglycinate tablets) 0.1 mg/0.02 mg and 36.5 mg - Rx Only - 1 Blister Packs, 28 tablets each - NDC ...
  • INGREDIENTS AND APPEARANCE
    Product Information